Tag: Genome Editing

Presently, there are several companies and universities, which are exploring the potential of gene editing technology beyond CRISPR for basic research, and the development of gene editing solutions. With the development of a versatile gene editing technology, including zinc-finger nucleases (ZFNs), TAL effector nucleases (TALENs), engineered endonucleases / meganucleases (EMNs) and clustered regularly interspaced short

At the American Society of Hematology (ASH) annual meeting in Orlando, the team, led by the Abramson Cancer Center of the University of Pennsylvania, will discuss two multiple myeloma patients and one sarcoma patient who is participating in a trial, which is also supported by Tmunity Therapeutics (a company that recently raised $75 million in

The rising demand for genome editing services has resulted in the rise of several players in the last few years. Around 61% of the companies that offer these services are based in North America. To get more free insights about the genome editing services market, check out the report Genome Editing Services market report.

As per a recent market report by Roots Analysis, cell line engineering is the most popular service, provided by close to 31% of the CRISPR based genome editing service providers. To get additional free insights about the genome editing services market, check out the report Genome Editing Services Market Report.

The rising demand for genome editing services has resulted in the rise of several players with a wide range of capabilities. Currently, there are close to 80 players that claim to offer CRISPR based genome editing services. To get more insights about the market, check out the detailed report market report – Genome Editing Services.

Intellia Therapeutics, one of the leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology is presenting one oral presentation and four poster presentations at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) meeting taking place October 22-25, 2019, in Barcelona, Spain. Get a complete

Gene editing companies around the word are debating the scientific and ethical possibilities of using powerful genome editing tools, such as the CRISPR gene editing therapies, to treat heritable diseases in human embryos. In 1987, the discovery of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) genes in single celled prokaryotic systems revolutionized genetic engineering.